Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

eptinezumab

- PMLiVE

Lundbeck and Takeda submit depression drug for US approval

Brintellix could help Lundbeck overcome loss of patent protection for Lexapro/Cipralex

- PMLiVE

Gilead expands in cancer with $510m YM BioSciences deal

Lands JAK inhibitor CYT387

- PMLiVE

Baxter expands kidney disease business with $4bn Gambro deal

Strengthens haemodialysis portfolio with purchase of Swedish medical tech firm

- PMLiVE

GSK raises stake in Nigerian unit

Set to expand in growing market

- PMLiVE

Reckitt beats Bayer to acquire nutrition company Schiff

Provides springboard to US consumer health market

- PMLiVE

Lundbeck revenues fall on Lexapro competition

Reinforces need for successful vortioxetine launch

Pharma deals during October 2012

As pharma companies ramp up their activity after the summer, this month's dealmakers included Pfizer, AstraZeneca, Merck & Co and Bayer

- PMLiVE

Bayer makes $1.2bn bid for Schiff Nutrition, reports Q3

Boosts consumer health division as group sales climb 11.5 per cent

- PMLiVE

New CEO says AZ open to acquisitions to rebuild pipeline

Comments come as Q3 operating profit plummets 47 per cent

Pharma deals during September 2012

In this regular review of deals we focus on transactions announced during September 2012

- PMLiVE

Merck & Co pays €110m upfront for AiCuris’ CMV portfolio

Lead candidate is orphan drug letermovir for transplant patients

- PMLiVE

Sanofi acquires Colombian pharma manufacturing firm Genfar

Expands its Latin American generics portfolio

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links